AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00343421 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix®-IPV+Hib and Prevenar®
Description: 0.5 mL each, IM (opposite thigh)
Study NCT02872740 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Embolization of Left Gastric Artery
Description: Left gastric artery will be embolized to stasis with 150-250 micron polyvinyl alcohol particles
Study NCT02872740 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Embolization of Gastroepiploic Artery
Description: Gastroepiploic artery will be embolized to stasis with 150-250 micron polyvinyl alcohol particles
Study NCT02645357 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: computer reminders on clinical practice
Description: on-screen, point-of-care computer reminders on clinical practice.
Study NCT02645357 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: control group
Study NCT01609907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin+Valsartan (Sequence 1)
Description: Period 1(A) Period 2(B) Period 3(C) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
Study NCT01609907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin+Valsartan (Sequence 2)
Description: Period 1(C) Period 2(A) Period 3(B) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
Study NCT01609907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin+Valsartan (Sequence 3)
Description: Period 1(B) Period 2(C) Period 3(A) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
Study NCT03507387 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: 1ml 0.9% normal saline intramuscular injection will be given into the gluteus maximus muscle before anesthesia and after the subarachnoid injection is completed.
Study NCT03507387 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 1ml 0.9% normal saline intramuscular injection will be given into the gluteus maximus muscle before anesthesia and after the subarachnoid injection is completed.
Study NCT03507387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: All patients will receive spinal anesthesia with bupivacaine.
Study NCT03507387 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: All patients will receive spinal anesthesia with bupivacaine.
Study NCT03507387 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine
Description: All patients will receive spinal anesthesia with bupivacaine.
Study NCT01146717 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Patients with mild cognitive impairment will undergo moderate intensity endurance exercise training for one year.
Study NCT01146717 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Balance training
Description: A group of patients with mild cognitive impairment will perform flexibility and balance training for one year as a control group.
Study NCT01609907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin+Valsartan (Sequence 4)
Description: Period 1(C) Period 2(B) Period 3(A) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
Study NCT01609907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin+Valsartan (Sequence 5)
Description: Period 1(B) Period 2(A) Period 3(C) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
Study NCT01609907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin+Valsartan (Sequence 6)
Description: Period 1(A) Period 2(C) Period 3(B) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
Study NCT00423917 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Study NCT00423917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fulvestrant
Study NCT03807921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Oral anticoagulation
Study NCT02131558 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ICG Dye
Description: ICG Dye injections
Study NCT01677533 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Data
Description: The microsystem teams of providers, nurses, and clerks will receive monthly reports of their performance measures, which will include process and outcome data for smoking cessation and blood pressure control for veterans in their panel. The reports will provide lists of individual patients in the panel with unmet goals on VA performance measures. They will receive written informational material describing principles and practices of panel management and evidence-based guidelines for hypertension management and smoking cessation.
Study NCT01677533 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Data
Description: The microsystem teams of providers, nurses, and clerks will receive monthly reports of their performance measures, which will include process and outcome data for smoking cessation and blood pressure control for veterans in their panel. The reports will provide lists of individual patients in the panel with unmet goals on VA performance measures. They will receive written informational material describing principles and practices of panel management and evidence-based guidelines for hypertension management and smoking cessation.
Study NCT01677533 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Panel Management Support
Description: PMAs will meet regularly with the members of the microsystem team for one hour/week. The team will be asked to review progress on the health status of their patient panel and to plan strategies for improving their outcomes that the PMA will then implement. A PMA toolkit of panel management strategies will be established that will include guidelines for using VA databases to identify care gaps and reaching out to panel patients via phone and mail to intervene (e.g. reconnect patients to care with appointments, assess and enhance medication adherence, connect patients with VA services, motivational interviewing, and communication with the team about patient issues.
Study NCT03807921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Antiplatelet treatment
Study NCT03807921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Antiplatelet treatment
Study NCT01677533 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: The educational intervention will be administered throughout the duration of the study. Our initial educational focus will be on content (concepts of population health and panel management) and process (practice change methodology). Subsequent education will be process oriented, reviewing the changing system of care and discussing its functioning. Education will cover panel management strategies, microsystem theory and skills, and specific strategies regarding the management of hypertension and smoking cessation. It will include monthly seminars, reading materials, web-based modules, and skill building workshops, and PMA-conducted monthly academic detailing using panel data and feedback. After the first three months, academic detailing will only be implemented on an as-needed basis.
Study NCT03842423 — intervention group
Intervention type: PROCEDURE
Intervention: Brachial Plexus Anaesthesia
Description: Regional anaesthesia for treatment of upper extremity injuries.
Study NCT03085797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Description: Mepolizumab injection 100 mg/millilitre (mL) is a clear to opalescent, colorless to pale yellow to pale brown sterile solution for SC injection in a single-use, safety syringe.
Study NCT03085797 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a clear to opalescent, colorless sterile solution for SC injection in a single-use, safety syringe.
Study NCT03085797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate
Description: All participants will receive mometasone furoate usually 400 micrograms (mcg), 2 actuations (50 mcg/actuation) in each nostril twice daily. Intolerant participants will use 200g (2 actuations \[50 g/actuation\] in each nostril once daily).
Study NCT03085797 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mometasone furoate
Description: All participants will receive mometasone furoate usually 400 micrograms (mcg), 2 actuations (50 mcg/actuation) in each nostril twice daily. Intolerant participants will use 200g (2 actuations \[50 g/actuation\] in each nostril once daily).
Study NCT00697138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: d-Amphetamine; Atomoxetine
Description: Dexedrine (0-60 mg/day); Strattera (0-80 mg/day)
Study NCT04161248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Dose Level -1: Venetoclax 200 mg/day days 4-8 cycle 1, days 1-5 cycle 2 and 3, + R-GDP~Dose Level 1: Venetoclax 200 mg/day days 4-10 cycle 1, days 1-10 cycle 2 and 3, + R-GDP~Dose Level 2: Venetoclax 400 mg/day days 4-10 cycle 1, days 1-10 cycle 2 and 3, + R-GDP~Dose Level 3: Venetoclax 800 mg/day days 4-10 cycle 1, days 1-10 cycle 2 and 3, + R-GDP
Study NCT04161248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab Injection
Description: 375 mg/m2 - Day 1, cycle 1.
Study NCT04161248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab SC
Description: 1400 mg fixed dose - Day 1, cycle 2 and 3
Study NCT01409733 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TACE using Drug Eluting Beads loaded with Doxorubicin
Description: 100-300 microns DC Beads loaded with Doxorubicin (75mg of Doxorubixcin per vial)
Study NCT04161248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m2 - Day 1 to day 8
Study NCT04065555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-981
Description: Intratumoral microdose injection by the CIVO device.
Study NCT04065555 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Intratumoral microdose injection by the CIVO device.
Study NCT04065555 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Intratumoral microdose injection by the CIVO device.
Study NCT04065555 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TAK-981 + Cetuximab
Description: Intratumoral microdose injection by the CIVO device.
Study NCT04065555 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TAK-981 + Avelumab
Description: Intratumoral microdose injection by the CIVO device.
Study NCT02185950 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound
Study NCT02185950 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: paraffin
Study NCT02185950 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: endermotherapy
Study NCT02678481 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR-guided in-bore prostate biopsy
Description: 2 targeted biopsy cores from each prostate lesion detected at multiparametric MR imaging
Study NCT04161248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg daily - Day 1 to day 4
Study NCT04161248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75mg/m2 - Day 1
Study NCT02678481 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TRUS-guided prostate biopsy
Description: 24-28 systematic biopsy core (saturation scheme)
Study NCT02960828 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subthreshold Laser Photocoagulation
Description: Selective Subthreshold Laser Photocoagulation is applied to the periphery of high-risk macular drusen
Study NCT02960828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravitreal Anti-VEGF injection
Description: To prevent choroidal neovascularization, intravitreal Anti-VEGF injection is done on a 3 month interval up to 1 year.
Study NCT04161248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: Cycle 1: Glofitamab 2.5 mg (day 8) and 10 mg (day 15) + R-GDP Cycle 2: Glofitamab 30 mg (day 8) + R-GDP Cycle 3: Glofitamab 30 mg (day 8) + R-GDP
Study NCT04161248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafasitamab
Description: Cycle 1: Tafasitamab (12 mg/kg IV day -1, 8, 15) Cycles 2 and 3: Tafasitamab (12 mg/kg IV day 1, 8, 15)
Study NCT02960828 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Subthreshold Laser
Study NCT00859911 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multiple micronutrients
Description: A tablet on three days a week containing: Vitamin A 1500 µg, Vitamin D 15 µg, Thiamine Mononitrate 1.22 mg, Riboflavin 1.7 mg, Ascorbic Acid 60 mg, Niacin amide 20 mg, Pyridoxine hydrochloride 2 mg, Folic Acid 400 µg, Calcium pantothenate 10.8 mg, Cyanocoblamin 6 µg, Vitamin E 18 IU, ferrous sulphate 19 mg, potassium iodide 145 µg, Potassium sulphate 11 mg, Manganese sulphate 0.38 mg, copper sulphate 0.509 mg, zinc sulphate 15 mg
Study NCT00750958 — intervention group
Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: NetGuard Automated Clinician Alert System
Description: Monitoring System for in-hospital patients who are typically unmonitored. Identifies and alarms for cardiac rhythm changes.
Study NCT00859911 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multiple micronutrients
Description: A tablet on three days a week containing: Vitamin A 1500 µg, Vitamin D 15 µg, Thiamine Mononitrate 1.22 mg, Riboflavin 1.7 mg, Ascorbic Acid 60 mg, Niacin amide 20 mg, Pyridoxine hydrochloride 2 mg, Folic Acid 400 µg, Calcium pantothenate 10.8 mg, Cyanocoblamin 6 µg, Vitamin E 18 IU, ferrous sulphate 19 mg, potassium iodide 145 µg, Potassium sulphate 11 mg, Manganese sulphate 0.38 mg, copper sulphate 0.509 mg, zinc sulphate 15 mg
Study NCT01077843 — intervention group
Intervention type: DRUG
Intervention: Etoricoxib
Description: Cox-2 inhibitor
Study NCT01077843 — intervention group
Intervention type: DRUG
Intervention: Other Cox-2 inhibitors
Description: Cox-2 inhibitor
Study NCT01077843 — intervention group
Intervention type: DRUG
Intervention: Other Non-selective NSAIDs
Description: Non-selective NSAID
Study NCT01077843 — intervention group
Intervention type: OTHER
Intervention: No anti-inflammatory treatment
Description: No anti-inflammatory prescription
Study NCT02933034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Manganese-enhanced MRI contrast reagent
Description: MRI using manganese-enhanced MRI contrast reagent (manganese 0.28 mL/kg).
Study NCT02933034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium-enhanced MRI contrast reagent
Description: MRI using gadolinium-enhanced MRI contrast reagent (gadolinium 0.2 mmol/kg).
Study NCT04052685 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Selective removal to soft dentin (SRSD)
Description: In order to prevent pulp exposure in deep caries lesions radiographically extending at least 3/4 of dentin, periphery of the cavity prepared to hard dentin while reasonable amount of soft carious tissue over the pulp is left. This caries removal strategy is termed selective removal to soft dentine.
Study NCT04052685 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Selective removal to firm dentine (SRFD)
Description: Carious tissue is totally removed until hard dentin dry in appearance and hard on probing. This carious removal strategy is strongly recommended for shallow or moderately deep carious lesions.
Study NCT04252846 — intervention group
Intervention type: DRUG
Intervention: Perampanel
Description: Perampanel oral tablets or oral suspension.
Study NCT04343625 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified yoga class
Description: Modified yoga was used to see if it would improve pain, fatigue, depression and anxiety, as well as improve sleep quality.
Study NCT03496220 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Angulus
Description: Feedback on patient recumbency
Study NCT03496220 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Angulus
Description: Feedback on patient recumbency
Study NCT01486927 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rVIII-SingleChain
Description: In Part 1 of the study, subjects received a single intravenous infusion of 50 IU/kg recombinant, single-chain coagulation factor VIII (rVIII-SingleChain) preceded by a 4-day washout period. In Parts 2 and 3 of the study, subjects received repeat injections of rVIII-SingleChain either as an on-demand or prophylaxis regimen at a dose and frequency determined by their study doctor. Subjects participating in the Part 3 PK analyses received a single infusion of 50 IU/kg rVIII-SingleChain and a repeat dose of the same strength of rVIII-SingleChain after 3 to 6 months. Subjects from Parts 2 and 3 participating in the surgical substudy received an individualized dose regimen of rVIII-SingleChain, based on the type of surgery and the clinical status of the subject.
Study NCT01486927 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Octocog alfa
Description: In Part 1 of the study, subjects received a single intravenous infusion of 50 IU/kg of octocog alfa preceded by a 4-day washout period. Octocog alfa is the international nonproprietary name (INN) for recombinant human coagulation factor VIII.
Study NCT04075721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M3258
Description: Participants received M3258 at a dose of 10 milligrams (mg) orally, once daily (QD) or twice per week on Day 1 and Day 4 until disease progression.
Study NCT04075721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M3258 20 mg
Description: Participants received M3258 at a dose of 20 mg orally, twice per week on Day 1 and Day 4 until disease progression.
Study NCT01910259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiloride
Description: Comparison with placebo
Study NCT01910259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole
Description: Comparison with placebo
Study NCT01910259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Comparison with placebo
Study NCT01910259 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study NCT03175900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naoan dripping pills
Description: Patients will take 20 pills(1000mg) after meal twice a day for 12 weeks, Fenbid can be taken if headache is unbearable, but make sure the records(including attack time, drug dosage, pain intensity and duration) are written down as detailed as possible.~Procedure: MRI scanning (fMRI and DTI）
Study NCT03175900 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will take 20 pills(1000mg) after meal twice a day for 12 weeks, Fenbid can be taken if headache is unbearable, but make sure the records(including attack time, drug dosage, pain intensity and duration) are written down as detailed as possible.~Procedure: MRI scanning (fMRI and DTI)
Study NCT01761084 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and behaviour change strategies
Description: 1. cardiovascular exercise (e.g., marching, walking) for ≥10 minutes per day~2. postural retraining and balance exercises ≥3 days a week (will be encouraged to do these daily)~3. perform muscle strengthening and balance training exercises ≥ 3 days a week~4. the exercise intervention was developed using the Bone Fit program as a framework (http://www.bonefit.ca/). The physical therapist will tailor exercises and work with participant to integrate them into their day.
Study NCT02106052 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise
Description: The aerobic exercise condition is a graduated program of supervised aerobic exercise up to one hour per day, three days per week, and lasting 6 months. The structured exercise portion of the sessions will initially last for 15-20 minutes at 40-50% heart rate reserve (HRR) and progressively increase up to 35-40 minutes in duration at 65-75% HRR during the last month of the program. The program will focus on large, dynamic movements of the lower extremities (e.g. leg cycling ergometry). There may be some individual variation in adaptations that dictate the exact characteristics of the program.
Study NCT02106052 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Stretching and toning exercise
Description: The stretching and toning condition is a supervised stretching program with Therabands up to one hour per day, three days per week, and lasting 6 months. The stretching exercises will be based on a manual published by the National Multiple Sclerosis Society (NMSS) that has been standardized, manualized for reproducibility, and the investigators will progressively include more exercises and sets with Therabands for resistance over the course of the 6-month period.
Study NCT00940589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Circadin
Description: Prolonged Release melatonin (Circadin) 2mg tablets